23/10/2025 07:57
EQS-News: Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Heidelberg Pharma AG / Key words: Miscellaneous br/ Heidelberg Pharma’s Lead ADC Candidate HDP101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma... Lire...
09/10/2025 07:03
EQS-News: Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Heidelberg Pharma AG / Key words: Quarterly / Interim Statement br/ Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025 br/br/ 09.10.2025 / 07:03... Lire...
06/10/2025 15:58
EQS-Adhoc: Heidelberg Pharma AG Announces Updated Guidance
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd pEQSAdhoc: Heidelberg Pharma AG / Key words: Change in Forecastbr/ Heidelberg Pharma AG Announces Updated Guidance br/br/ 06Oct2025 / 15:58 CET/CESTbr/ Disclosure of an inside information acc. to Article 17 MAR of... Lire...
25/09/2025 13:17
EQS-News: Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Heidelberg Pharma AG / Key words: Study results br/ Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP101 in Multiple Myeloma... Lire...
25/09/2025 10:51
EQS-News: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Heidelberg Pharma AG / Key words: Strategic Company Decision br/ Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP101 Due to Delayed... Lire...
25/09/2025 10:46
EQS-Adhoc: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd pEQSAdhoc: Heidelberg Pharma AG / Key words: Strategic Company Decisionbr/ Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP101 Due to Delayed Milestone Payment... Lire...
04/09/2025 09:46
EQS-News: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Heidelberg Pharma AG / Key words: Conference br/ Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP101 to be Presented at International Myeloma Society Annual... Lire...
28/08/2025 03:50
EQS-Adhoc: Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd pEQSAdhoc: Heidelberg Pharma AG / Key words: Financingbr/ Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250CDx br/br/ 28Aug2025 / 03:50... Lire...
10/07/2025 07:03
EQS-News: Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Heidelberg Pharma AG / Key words: Half Year Report br/ Heidelberg Pharma Reports on First HalfYear 2025 and the Positive Course of Business br/br/ 10.07.2025 / 07:03... Lire...